Multicentre study with viloxazine (Vivalan) in depressed patients.

  title={Multicentre study with viloxazine (Vivalan) in depressed patients.},
  author={J. Kabe{\vs} and T. Dostal and K. N{\'a}hunek and J. {\vS}vestka and J. Molcan and T. Caplov{\'a} and K. Hynek and F. Faltus and R. Holland},
  journal={International pharmacopsychiatry},
  volume={15 4},
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
The chemical properties, mechanism of action, safety, and tolerability across these studies are reviewed, and the contemporary rationale for the development of this agent as an extended-release oral formulation for the treatment of attention-deficit/hyperactivity disorder is discussed. Expand
Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy Adults.
This trial investigated the pharmacokinetics and safety of SPN-812 coadministered with the potent CYP2D6 inhibitor paroxetine and reported a modest change on viloxazine AUCs with no change in Cmax. Expand
Age, therapeutic “milieu” and clinical outcome in depressive patients treated with viloxazine: A study with plasma levels
The satisfactory antidepressant activity and the good tolerability of viloxazine in elderly depressed patients make this drug particularly suitable for using in ambulant geriatric depressed patients. Expand